Sustainable weight loss is rarely about willpower — it's about the right clinical plan for your body, history, and goals. Our medical weight management program blends nutritional guidance, lifestyle changes, and — when clinically appropriate — modern prescription therapies.
Yes — NuThera offers physician-supervised medical weight management in Las Vegas, including FDA-approved GLP-1 medications (semaglutide, tirzepatide) when clinically appropriate. Our program combines a comprehensive metabolic evaluation, individualized nutrition guidance, GLP-1 therapy when indicated, and ongoing clinical supervision — not a one-size-fits-all package or a one-time prescription. HSA/FSA and Afterpay accepted.
Medical weight management is a physician-supervised program for sustainable weight loss in adults with obesity or weight-related health conditions. It combines a comprehensive metabolic and behavioral evaluation with nutrition guidance, lifestyle coaching, and FDA-approved medications (most commonly GLP-1 receptor agonists) when clinically indicated — distinct from commercial diet programs that don't include medical evaluation, prescription oversight, or clinical monitoring.
GLP-1 medications work by mimicking a natural hormone (glucagon-like peptide-1) that regulates appetite and blood sugar. They slow stomach emptying, reduce hunger signals, and improve insulin sensitivity. At NuThera, the physician evaluates your metabolic and hormonal baseline (including labs and risk factors), prescribes the appropriate medication and dose, monitors response monthly during titration, and adjusts the plan based on weight, side effects, and lab follow-ups at 3 and 6 months.
Every weight loss patient receives the following as part of their care at NuThera.
Not sure if this fits? Call us at (725) 726-7914 — we'll help you figure it out.
Specific criteria help you (and us) know quickly whether this service fits your situation.
Here's what each step looks like — from your first call to ongoing care. We'll always tell you in advance what's coming next.
Comprehensive history, physical exam, weight and metabolic history, current medications, and goals. We discuss the realistic range of outcomes — both with and without medication — so you can make an informed decision.
Comprehensive metabolic panel, A1c, lipid panel, thyroid, kidney function, and (when indicated) liver enzymes and vitamin levels. Results return within 2–3 business days.
Individualized nutrition guidance, behavior strategies, and — when clinically appropriate — a GLP-1 prescription. We discuss medication options, dosing, side-effect management, and what coverage looks like before you fill the first prescription.
Dose escalation happens gradually to minimize side effects. Each monthly visit reviews weight, side effects, blood pressure, blood glucose, and any plan adjustments. Most patients reach their target maintenance dose within 4 months.
Once you're on a stable dose, visits space out to every 8–12 weeks. Labs repeat at 3 and 6 months. We discuss long-term strategy: continue, taper, or transition to maintenance — based on your weight loss, lifestyle changes, and goals.
Insurance coverage for GLP-1 weight management varies dramatically. Many commercial plans cover GLP-1 prescriptions for type 2 diabetes; fewer cover the same medications for weight loss alone, and several have added prior-authorization requirements in 2024–2025. We verify your specific benefits before prescribing and tell you the realistic out-of-pocket cost in advance — no surprise bills.
Commercial programs offer behavior coaching and structure but no medical evaluation, no prescription medications, and no clinical monitoring. They work for some patients with mild weight loss goals and no underlying metabolic issues. Medical weight management adds physician oversight, lab monitoring, and access to GLP-1 medications — relevant when commercial programs haven't worked or when there are weight-related health conditions to manage.
Bariatric surgery (gastric sleeve, bypass) produces faster and larger weight loss — typically 25–35% of body weight over 1–2 years — with corresponding long-term maintenance. It's usually considered for BMI ≥40, or BMI ≥35 with serious comorbidities. Medical weight management is non-surgical, lower-risk, and works for a broader BMI range, with typical sustained loss of 15–22% on GLP-1 therapy. Many patients use medical management as a first step or as a long-term alternative to surgery.
Branded GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) are FDA-approved, manufactured under strict quality controls, and dosed in well-studied amounts. Compounded GLP-1s come from non-FDA-regulated compounding pharmacies — the FDA has issued multiple safety warnings about dosing errors, contamination, and ingredient inconsistencies. NuThera prescribes branded only.
When clinically appropriate, yes. GLP-1 medications (semaglutide — Ozempic/Wegovy; tirzepatide — Mounjaro/Zepbound) are powerful tools for weight management, but they aren't right for every patient. We evaluate your health history, lab work, and goals before recommending a medication. Ongoing clinical supervision is part of every program.
Coverage varies significantly by plan and by medication. Some commercial plans cover GLP-1 therapy when prescribed for type 2 diabetes; coverage for weight loss alone is rarer and increasingly restrictive. We verify your benefits before starting treatment so you know what's covered and what the cash-pay alternatives look like. HSA/FSA and Afterpay are accepted for self-pay components.
Safe, sustainable weight loss is typically 1–2 pounds per week with lifestyle changes alone, and 1–4% of body weight per month with GLP-1 therapy (faster in the first 3 months, slower as you approach a stable weight). Faster loss increases risk of muscle loss, gallstones, and rebound weight gain. We design programs for sustainable results, not crash outcomes.
Most common side effects are gastrointestinal — nausea, constipation, or diarrhea — especially during the first few weeks and after dose increases. These usually subside as your body adjusts. Less common but more serious risks include pancreatitis, gallbladder issues, and (in patients with personal or family history) thyroid C-cell tumors. We screen for risk factors before prescribing and monitor you closely throughout treatment.
GLP-1 medications work while you're taking them. When patients stop without sustained lifestyle change, weight typically returns over 12–24 months — often most of it. That's why our program emphasizes nutrition and behavior alongside medication, so the weight stays off if and when you taper down or stop. We also help patients explore long-term maintenance dosing if appropriate.
We prescribe FDA-approved branded GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro). Compounded versions from non-FDA-regulated facilities have raised serious safety concerns from the FDA and are not part of our program. Cost is a real concern for many patients — if branded medications aren't accessible, we'll discuss alternative clinical strategies rather than route you toward unregulated compounded products.
Most adults with a BMI ≥30, OR BMI ≥27 with a related condition (type 2 diabetes, hypertension, sleep apnea, fatty liver, joint pain), qualify for medical weight management. Patients with active eating disorders, certain pancreas conditions, or specific cancer histories may not be candidates for GLP-1 therapy specifically — we'll discuss alternative approaches at your evaluation.
An initial 60-minute evaluation, then monthly visits during the first 3–4 months while we titrate medication and monitor response. After you reach a stable maintenance dose, visits typically space out to every 8–12 weeks. Labs are repeated at 3 and 6 months to monitor metabolic and kidney function.
Specialized recovery care for Department of Labor–covered injuries, delivered with the clinical and documentation rigor federal claims require.
Evidence-based physical therapy and rehabilitation for work-related, sports, and accident injuries — built to restore function, not just reduce pain.
Medical-led personal injury care that starts with an MD/PA evaluation and moves into structured physical therapy — built for recovery and defensible documentation.